======= MEF2A =======


== Gene Information ==
  * **<color #00a2e8>Official Symbol</color>**: MEF2A
  * **<color #00a2e8>Official Name</color>**: myocyte enhancer factor 2A
  * **<color #00a2e8>Aliases and Previous Symbols</color>**: N/A
  * **<color #00a2e8>Entrez ID</color>**: [[https://www.ncbi.nlm.nih.gov/gene/?term=4205|4205]]
  * **<color #00a2e8>UniProt</color>**: [[https://www.uniprot.org/uniprot/Q02078|Q02078]]
  * **<color #00a2e8>Interactions</color>**: [[https://thebiogrid.org/search.php?search=MEF2A&organism=9606|BioGRID]]
  * **<color #00a2e8>PubMed articles</color>**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20MEF2A|Open PubMed]]
  * **<color #00a2e8>OMIM</color>**: [[https://omim.org/entry/600660|Open OMIM]]

== Function Summary ==
  * **<color #00a2e8>Entrez Summary</color>**:  The protein encoded by this gene is a DNA-binding transcription factor that activates many muscle-specific, growth factor-induced, and stress-induced genes. The encoded protein can act as a homodimer or as a heterodimer and is involved in several cellular processes, including muscle development, neuronal differentiation, cell growth control, and apoptosis. Defects in this gene could be a cause of autosomal dominant coronary artery disease 1 with myocardial infarction (ADCAD1). Several transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Jan 2010]. 
  * **<color #00a2e8>UniProt Summary</color>**: N/A

<button type='primary' size='sm' modal='Pfam_Domains'>Pfam Domains</button>
<button type='primary' size='sm' modal='GO_terms'>GO Terms</button>


<modal id='Pfam_Domains' size='lg' title='Pfam Domains'>
|SRF-TF|
|HJURP C|
</modal>

<modal id='GO_terms' size='lg' title='GO Terms'>
|ERK5 cascade|
|ventricular cardiac myofibril assembly|
|ventricular cardiac muscle cell development|
|ventricular cardiac muscle cell differentiation|
|mitochondrion distribution|
|mitochondrial genome maintenance|
|cardiac myofibril assembly|
|histone acetyltransferase binding|
|positive regulation of cardiac muscle hypertrophy|
|positive regulation of muscle hypertrophy|
|activating transcription factor binding|
|positive regulation of glucose import|
|positive regulation of glucose transmembrane transport|
|mitochondrion localization|
|SMAD binding|
|regulation of glucose import|
|regulation of cardiac muscle hypertrophy|
|dendrite morphogenesis|
|regulation of muscle hypertrophy|
|cardiac muscle cell development|
|RNA polymerase II transcription factor binding|
|cardiac cell development|
|myofibril assembly|
|regulation of glucose transmembrane transport|
|cellular response to calcium ion|
|regulation of muscle adaptation|
|positive regulation of muscle cell differentiation|
|cardiac muscle cell differentiation|
|cardiac conduction|
|dendrite development|
|cellular component assembly involved in morphogenesis|
|histone deacetylase binding|
|actomyosin structure organization|
|cardiocyte differentiation|
|multicellular organismal signaling|
|striated muscle cell development|
|muscle cell development|
|response to calcium ion|
|regulation of muscle cell differentiation|
|cardiac muscle tissue development|
|cellular response to metal ion|
|striated muscle cell differentiation|
|positive regulation of transmembrane transport|
|transcription factor complex|
|cellular response to inorganic substance|
|regulation of muscle system process|
|nuclear chromatin|
|regulation of heart contraction|
|muscle cell differentiation|
|striated muscle tissue development|
|transcription coactivator activity|
|regulation of blood circulation|
|muscle organ development|
|muscle tissue development|
|RNA polymerase II regulatory region sequence-specific DNA binding|
|response to metal ion|
|MAPK cascade|
|signal transduction by protein phosphorylation|
|chromatin binding|
|sequence-specific DNA binding|
|cell morphogenesis involved in neuron differentiation|
|mitochondrion organization|
|DNA-binding transcription activator activity, RNA polymerase II-specific|
|supramolecular fiber organization|
|protein kinase binding|
|muscle structure development|
|neuron projection morphogenesis|
|plasma membrane bounded cell projection morphogenesis|
|protein heterodimerization activity|
|cell projection morphogenesis|
|actin cytoskeleton organization|
|RNA polymerase II proximal promoter sequence-specific DNA binding|
|cell part morphogenesis|
|heart development|
|response to inorganic substance|
|cell morphogenesis involved in differentiation|
|regulation of transmembrane transport|
|actin filament-based process|
|organelle localization|
|regulation of system process|
|transcription, DNA-templated|
|nucleic acid-templated transcription|
|RNA biosynthetic process|
|neuron projection development|
|DNA-binding transcription factor activity|
|cell morphogenesis|
|organelle assembly|
|neuron development|
|cellular component morphogenesis|
|negative regulation of transcription by RNA polymerase II|
|circulatory system development|
|anatomical structure formation involved in morphogenesis|
|apoptotic process|
|positive regulation of cell differentiation|
|protein phosphorylation|
|positive regulation of transport|
|neuron differentiation|
|programmed cell death|
|cell death|
|nucleobase-containing compound biosynthetic process|
|cytoskeleton organization|
|plasma membrane bounded cell projection organization|
|cell projection organization|
|heterocycle biosynthetic process|
|aromatic compound biosynthetic process|
|negative regulation of transcription, DNA-templated|
|positive regulation of transcription by RNA polymerase II|
|negative regulation of nucleic acid-templated transcription|
|negative regulation of RNA biosynthetic process|
|phosphorylation|
|organic cyclic compound biosynthetic process|
|negative regulation of RNA metabolic process|
|positive regulation of developmental process|
|negative regulation of cellular macromolecule biosynthetic process|
|negative regulation of nucleobase-containing compound metabolic process|
|negative regulation of macromolecule biosynthetic process|
|negative regulation of cellular biosynthetic process|
|generation of neurons|
|positive regulation of transcription, DNA-templated|
|negative regulation of biosynthetic process|
|DNA-binding transcription factor activity, RNA polymerase II-specific|
|neurogenesis|
|cellular nitrogen compound biosynthetic process|
|positive regulation of nucleic acid-templated transcription|
|positive regulation of RNA biosynthetic process|
|cell development|
|RNA metabolic process|
|intracellular signal transduction|
|cellular macromolecule biosynthetic process|
|negative regulation of gene expression|
|positive regulation of RNA metabolic process|
|positive regulation of multicellular organismal process|
|tissue development|
|macromolecule biosynthetic process|
|regulation of cell differentiation|
|regulation of transport|
|positive regulation of nucleobase-containing compound metabolic process|
|positive regulation of macromolecule biosynthetic process|
|positive regulation of cellular biosynthetic process|
|positive regulation of gene expression|
|gene expression|
|positive regulation of biosynthetic process|
</modal>
\\

 === CRISPR Data ===
<button type='primary' size='small' modal='Compound_Hit'>Compound Hit</button>
<button type='default' size='small' modal='Most_Correlated_Genes'>Most Correlated Genes in Chemogenomics</button>
<button type='primary' size='small' modal='Essential_Avana'>Tissues where Essential in the Avana Dataset (DepMap 20Q1)</button>

<modal id='Compound_Hit' size='lg' title='Compound Hit'>
^Screen^Score^
|[[:results:exp30|Rapamycin 10μM R00 exp30]]|-2.74|
|[[:results:exp84|UM0125461 0.74μM R02 exp84]]|-2.43|
|[[:results:exp222|Betulinic acid 10 to 15μM on day4 R05 exp222]]|-2.3|
|[[:results:exp445|∆-9-Tetrahydrocannabinol 30μM R08 exp445]]|-2.28|
|[[:results:exp15|Cycloheximide 0.2μM R00 exp15]]|-2.08|
|[[:results:exp31|Rifampicin 1μM R00 exp31]]|-2.05|
|[[:results:exp229|Dimethyloxaloylglycine 100μM R05 exp229]]|-2.04|
|[[:results:exp106|UM131593 0.2μM R03 exp106]]|-1.95|
|[[:results:exp499|LY2090314 0.003μM R08 exp499]]|-1.94|
|[[:results:exp35|TRAIL 5ng/ml R00 exp35]]|-1.94|
|[[:results:exp316|Geldanamycin 0.015 to 0.025μM on day4 R07 exp316]]|-1.8|
|[[:results:exp36|TRAIL 50ng/ml R00 exp36]]|-1.8|
|[[:results:exp169|BH1 1μM R04 exp169]]|-1.77|
|[[:results:exp14|Cycloheximide 0.02μM R00 exp14]]|-1.77|
|[[:results:exp530|Thioridazine 5μM R08 exp530]]|-1.77|
|[[:results:exp269|Bisphenol A 100μM R06 exp269]]|-1.71|
|[[:results:exp434|Vemurafenib 6.6μM R08 exp434]]|-1.71|
|[[:results:exp272|CHIR-124 0.04μM R06 exp272]]|1.75|
|[[:results:exp50|Nicotinamide 2000μM R01 exp50]]|1.76|
|[[:results:exp46|HMS-I1 1μM R01 exp46]]|1.8|
|[[:results:exp51|Nifuroxazide 1μM R01 exp51]]|2.35|
</modal>

<modal id='Most_Correlated_Genes' size='lg' title='Most Correlated Genes in Chemogenomics'>
No correlation found to any other genes in chemogenomics.
</modal>

<modal id='Essential_Avana' size='lg' title='Tissues where Essential in the Avana Dataset (DepMap 20Q1)'>
Global Fraction of Cell Lines Where Essential: 0/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/26|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/16|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/16|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
</modal>

== Essentiality in NALM6  ==
    * **<color #00a2e8>Essentiality Rank</color>**: 3899
    * **<color #00a2e8>Expression level (log2 read counts)</color>**: 7.57 
<button type='primary' size='small' modal='Dist_expr'>Expression Distribution</button>
<modal id='Dist_expr' size='lg' title='MEF2A Expression in NALM6 Cells: 7.57'>
{{:chemogenomics:nalm6 dist.png?nolink |}}
</modal>